Press release
Uterine Fibroid Market is expected to reach USD 12.1 billion by 2034
Uterine Fibroid
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70740
In recent years, the uterine fibroid treatment market has undergone significant transformation, driven by advances in minimally invasive surgical techniques, new pharmacological options, and improved diagnostic imaging. Additionally, growing public awareness, increased healthcare access, and the expansion of women's health initiatives are fueling demand for early diagnosis and effective management.
The global uterine fibroid market is projected to grow from USD 6.5 billion in 2024 to USD 12.1 billion by 2034, at a CAGR of 6.4%, supported by innovations in both surgical and non-surgical treatment modalities.
Market Overview
• 2024 Market Size: USD 6.5 billion
• 2034 Forecast: USD 12.1 billion
• CAGR (2024-2034): 6.4%
• Key Growth Drivers: Rising incidence among women of reproductive age, preference for minimally invasive procedures, and availability of novel drug therapies.
• Challenges: Limited awareness in developing regions, recurrence rates post-treatment, and high costs for advanced therapies.
• Leading Players: Bayer AG, Pfizer Inc., AbbVie Inc., Myovant Sciences, Johnson & Johnson (Ethicon), Hologic Inc., and Boston Scientific Corporation.
The market is shifting toward patient-focused, fertility-preserving treatments and expanding its reach through digital health and remote consultation services.
Segmentation Analysis
By Treatment Type
• Surgical Procedures
o Hysterectomy
o Myomectomy (Laparoscopic, Hysteroscopic, Open)
o Uterine Artery Embolization (UAE)
o MRI-guided Focused Ultrasound Surgery (MRgFUS)
• Non-Surgical/Pharmacological Treatments
o Hormonal Therapy (GnRH Agonists & Antagonists, Oral Contraceptives, Progestins)
o Non-Hormonal Therapy (NSAIDs, Tranexamic Acid)
o Emerging Therapies (Selective Progesterone Receptor Modulators - SPRMs)
By Fibroid Type
• Intramural Fibroids
• Subserosal Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids
By End Use
• Hospitals
• Specialty Gynecology Clinics
• Ambulatory Surgical Centers
• Home Care (Pharmacological Treatment)
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary:
Surgical treatments, especially minimally invasive myomectomy, remain highly demanded for long-term relief, while non-surgical drug therapies are gaining popularity for symptom control, particularly in pre-surgical and fertility-focused patients.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70740/uterine-fibroid-market
Regional Analysis
North America
• Largest market share due to advanced healthcare infrastructure, high awareness, and insurance coverage for both surgical and non-surgical treatments.
• Strong adoption of MRgFUS and UAE for fertility preservation.
Europe
• Increased preference for minimally invasive approaches.
• Expanding use of SPRMs and hormonal therapies in early-stage management.
Asia-Pacific
• Fastest-growing region due to rising prevalence linked to lifestyle and hormonal factors.
• Urban healthcare infrastructure supporting adoption of advanced treatment modalities.
Middle East & Africa
• Limited access in rural regions but increasing treatment availability in urban hospitals.
• Growing public health initiatives targeting women's health.
Latin America
• Brazil and Mexico leading in surgical procedure volumes.
• Expanding market for affordable pharmacological treatments.
Regional Summary:
While North America dominates revenue, Asia-Pacific is projected to post the highest CAGR due to a large at-risk population, increased healthcare spending, and improved diagnostic access.
Market Dynamics
Key Growth Drivers
• Rising Prevalence: Increasing incidence among women in their 30s and 40s globally.
• Advancements in Minimally Invasive Surgery: Shorter recovery times and fertility preservation benefits.
• Pharmaceutical Innovations: New oral GnRH antagonists offering improved symptom control.
• Awareness Campaigns: Women's health advocacy reducing stigma and encouraging earlier diagnosis.
Key Challenges
• Recurrence Rates: Fibroids can reappear post-treatment, requiring repeated interventions.
• Cost Barriers: High costs of advanced surgical equipment and branded medications.
• Unequal Access: Disparities in healthcare infrastructure limit treatment adoption in developing regions.
Latest Trends
• Development of oral once-daily GnRH antagonists with add-back therapy to minimize side effects.
• Increased use of robotic-assisted myomectomy for precision surgery.
• Integration of AI in ultrasound imaging for early detection.
• Growth of tele-gynecology platforms for remote treatment planning.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70740
Competitive Landscape
Major Players:
1. Bayer AG
2. Pfizer Inc.
3. AbbVie Inc.
4. Myovant Sciences
5. Johnson & Johnson (Ethicon)
6. Hologic Inc.
7. Boston Scientific Corporation
8. CooperSurgical Inc.
9. Ferring Pharmaceuticals
10. Intuitive Surgical Inc.
Competitive Summary:
The market is moderately consolidated, with leading players focusing on expanding their minimally invasive surgical device portfolios and launching new oral drug formulations. Partnerships between medtech firms and pharmaceutical companies are expected to accelerate the adoption of combination treatment models.
Conclusion and Outlook
The uterine fibroid market is on a strong growth trajectory, propelled by advancements in minimally invasive techniques, pharmaceutical innovation, and broader patient education initiatives. While North America remains the dominant market, Asia-Pacific offers the most significant long-term opportunities due to demographic and economic factors.
By 2034, the industry is likely to embrace personalized, fertility-preserving treatments, AI-enabled diagnostics, and hybrid care models combining in-person and virtual consultations. Companies prioritizing accessibility, affordability, and innovation will secure a competitive edge in this expanding sector.
This report is also available in the following languages : Japanese (子宮筋腫市場), Korean (자궁근종 시장), Chinese (子宫肌瘤市场), French (Marché des fibromes utérins), German (Markt für Uterusmyome), and Italian (Mercato dei fibromi uterini), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70740/uterine-fibroid-market#request-a-sample
Our More Reports:
Radiation induced-Oral Mucositis (RIOM) in Head and neck Cancer Market
https://exactitudeconsultancy.com/reports/70818/radiation-induced-oral-mucositis-riom-in-head-and-neck-cancer-market
Lip and Oral Cavity Cancer Market
https://exactitudeconsultancy.com/reports/70820/lip-and-oral-cavity-cancer-market
Periodontal Disease Market
https://exactitudeconsultancy.com/reports/70822/periodontal-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Fibroid Market is expected to reach USD 12.1 billion by 2034 here
News-ID: 4140128 • Views: …
More Releases from Exactitude Consultancy
Lip and Oral Cavity Cancer Market to Reach USD 6.42 Billion by 2034
Lip and oral cavity cancers - collectively known as oral cancers - encompass malignant tumors of the lips, tongue, gums, floor of the mouth, and inner lining of the cheeks. The global burden of this disease is significant, particularly in regions with high tobacco consumption, betel nut chewing, alcohol use, and poor oral hygiene.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70820
The increasing adoption of advanced diagnostic tools, targeted…
Radiation induced-Oral Mucositis (RIOM) in Head and neck Cancer Market to Reach …
Radiation-Induced Oral Mucositis (RIOM) in Head and Neck Cancer Market: Targeted Therapies and Supportive Care Innovations to Drive Growth Through 2034
The global RIOM in head and neck cancer market was valued at USD 480 million in 2024 and is projected to reach USD 885 million by 2034, growing at a CAGR of 6.3% during the forecast period.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70818
Key Highlights
• Growing incidence of head…
Erectile Dysfunction Devices Market to Reach USD 2.92 Billion by 2034
Erectile dysfunction (ED) is one of the most common male sexual health conditions, affecting over 300 million men globally by 2025. While oral medications such as PDE5 inhibitors (e.g., sildenafil) have dominated treatment, many patients seek non-pharmacological solutions due to drug side effects, contraindications, or preference for device-based interventions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70816
Erectile dysfunction devices - including vacuum devices (VEDs), constriction rings, and implants -…
Premature (PE) Market to Reach USD 4.31 Billion by 2034
Premature (PE) is the most common male sexual dysfunction, characterized by occurring sooner than desired, causing distress to one or both partners. Affecting an estimated 20-30% of men worldwide, PE can be lifelong (primary) or acquired (secondary) and is often linked to psychological, neurobiological, or hormonal factors.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70814
As awareness about men's sexual health increases and social stigma around seeking treatment diminishes, the…
More Releases for Fibroid
The Growing Uterine Fibroid Treatment Devices Market 2024-2032
In the realm of women's health, uterine fibroids represent a prevalent concern affecting millions globally. Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that develop in the muscular wall of the uterus. These growths can vary in size, number, and location within the uterus, and they can cause various symptoms such as heavy menstrual bleeding, pelvic pain or pressure, frequent urination, and reproductive issues including infertility and…
Uterine Fibroid Treatment Devices Market is estimated to be US$ 15.6 billion by …
The Uterine Fibroid Treatment Devices Market is a critical sector within women's healthcare, dedicated to developing and providing advanced medical devices for the diagnosis and treatment of uterine fibroids. Uterine fibroids, or leiomyomas, are noncancerous growths that occur in the uterus and can lead to various symptoms, impacting the health and well-being of many women. This market addresses the need for innovative and minimally invasive solutions to alleviate symptoms such…
Compassionate Care: Uterine Fibroid Treatment Devices
Uterine fibroids, non-cancerous growths that develop in the uterus, have become a pervasive health concern among women worldwide, especially those of childbearing age. These benign tumors can lead to a range of symptoms, such as heavy menstrual bleeding, pelvic pain, and fertility issues. With the escalating prevalence of uterine fibroids, there is a growing demand for innovative and effective treatment options. This has spurred the expansion of the Uterine Fibroid…
Uterine Fibroid Treatment Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Uterine Fibroid Treatment market analysis, which studies the Uterine Fibroid Treatment's industry coverage, current market competitive status, and market outlook and forecast by 2025.
Global “Uterine Fibroid Treatment Market 2020-2025” Research Report categorizes the global Uterine Fibroid Treatment market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players…
Japan Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023
ReportsWorldwide has announced the addition of a new report title Japan Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023 to its growing collection of premium market research reports.
GlobalData’s new report, "Japan Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023", provides key procedures data on the Japan Uterine Fibroid Embolization (UFE) Procedures. The report provides procedure volumes within market segments - Gastric Bypass Procedures, Gastric Banding Procedures, Sleeve Gastrectomy Procedures and…
Brazil Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023
ReportsWorldwide has announced the addition of a new report title Brazil Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023 to its growing collection of premium market research reports.
GlobalData’s new report, "Brazil Uterine Fibroid Embolization (UFE) Procedures Outlook to 2023", provides key procedures data on the Brazil Uterine Fibroid Embolization (UFE) Procedures. The report provides procedure volumes within market segments - Gastric Bypass Procedures, Gastric Banding Procedures, Sleeve Gastrectomy Procedures and…
